Coagulant Therapeutics is focused on developing innovative treatments for acute bleeding, a critical medical need that currently lacks approved therapies. Their lead candidate, CT-001, is a novel variant of Factor VIIa designed to enhance hemostatic activity while ensuring safety. This engineered molecule aims to provide rapid and effective intervention for conditions such as postpartum hemorrhage, traumatic brain injury, and other forms of trauma-related bleeding. The company leverages over a century of collective expertise in the coagulation cascade and biologics, along with a robust portfolio of patents, to optimize CT-001 for a wide patient population.

In addition to CT-001, Coagulant Therapeutics is exploring the potential of Activated Protein C (APC) as a therapeutic target for acute bleeding and related conditions. Their proprietary nanobody library, derived from llama antibodies, allows for the development of APC-targeted therapies that can selectively modulate its functions. This approach aims to address trauma-induced coagulopathy and other serious conditions, such as sepsis, by improving hemostatic control and reducing mortality. The company is committed to advancing these promising candidates through clinical development, with a focus on addressing significant unmet medical needs in the coagulation space.

United States

Coagulant Therapeutics seeks to address acute bleeding, a significant area of unmet medical need and includes the indications post partum hemorrhage, intracranial hemorrhage, traumatic brain injury and blunt trauma.

Coagulant Therapeutics

Company Details